Introduction
increased vascular resistance. We were finding that hypertrophy occurred early in hypertension; we began to see These observed differences might be important biologically, even though they were difficult to establish numericaltreatment study, that is, once hypertension and hyperly. The increased cardiac weight in young SHRs would trophy was established in this SHR model, and as a then be viewed as secondary to the increased pressure prevention study, to determine effects of antihypertensive overload. These two observations opened up new doors in drugs given to the animals from 3 weeks until 6 months of studying the relationship between blood pressure and age [9] . Two unexpected results were obtained in this cardiac mass and provided us with ideas to pursue this study: [1] a significant increase in ventricular weight was study further to dissect out the role of sympathetic outflow, found in very young SHRs; and [2] a marked difference plasma renin activity, and blood pressure in relationship to with regard to reversal or prevention of hypertrophy was ventricular mass. seen between two equipotent antihypertensive drugs (Figs.
The other unexpected observation is the effect of two 1-3).
antihypertensive therapies on arterial blood pressure and The alteration in ventricular weight during the developventricular weight, which confirmed the tentative conclument or reversal of cardiac hypertrophy was not due to sions drawn from the first part of the study, that is, the changes in water content since the dry weight to wet dissociation between the development of hypertrophy and weight ratio was basically the same in all groups of rats hypertension. Methyldopa and hydralazine were equally investigated. The increase in ventricular weight was successful in controlling blood pressure in the older rat or noticed before hypertension was recorded in the SHR. The in preventing its development in the younger SHR. In fact, expected parallelism between the rise in arterial pressure hydralazine was superior for both conditions, leading and the increase in cardiac weight had not occurred; this consistently to complete normalization of the blood pressure (methyldopa 149610 mm Hg vs. hydralazine 133610 mm Hg) (Fig. 2 ). Yet methyldopa reduced the ventricular weight of SHRs to almost control level, whereas hydralazine had no effect on established hypertrophy during either treatment or prevention therapy. The dissociation between actual pressure response to hydralazine and persistent cardiac hypertrophy has also been noted by other investigators in renal hypertension and tentatively ascribed to a cardiac stimulating effect. The difference between the two drugs could be due to their different hemodynamic effects, although it has been argued by some that chronic hydralazine treatment in men will not be associated with more rapid heart rate than treatment with methyldopa [11] . Obviously, our work dictated that further studies are needed to biochemically characterize the reversal of hypertrophy and its hemodynamic correlates. The plasma also suggested to be a good candidate and could be more than coincidental. The importance of hemodynamic factors I am glad for this opportunity to give a new generation in hypertensive heart disease is so obvious that a more some insight into our reasoning, and thus to give a voice to subtle or permissive role of associated hormonal or metamy co-authors Merlin Bumpus and Bob Tarazi and our bolic factors should also be considered. All these observaguiding light Irv Page, all now deceased. My career, like tions prompted us to determine the possible involvement of any scientist's, has seen trials of the scientific, political, factors such as: (a) hemodynamic changes, (b) hormonal and economic sort, but looking back, I cannot regret my changes, or (c) a combination of the sympathetic activity of choice to come to the Cleveland Clinic to contribute to the both agents or their combined influence in the enlargement world's hypertension research. Now as a senior invesof cardiac mass. Thus, we designed the experiments tigator, I still find satisfaction in the quest, including our performed in the cited article to evaluate the effects of laboratory's discovery of the novel protein myotrophin, various antihypertensive drugs with known mechanisms of and in the knowledge that I have introduced many younger action on cardiac mass. Accordingly, we studied the minds to the excitement of science and to the value of biochemical and humoral factors in SHRs and normotenbecoming part of the endless interplay of thesis, antithesis, sive Wistar-Kyoto control rats before and following synthesis -and the oftentimes surprising paradigm shift treatment with the vasodilator minoxidil and the b-blocker -that is modern biomedical science. propranolol. We measured blood pressure, heart size, and kidney and plasma renin activity. Our data showed that minoxidil effectively controlled blood pressure despite References marked and sustained increase in both plasma and kidney renin activity and that minoxidil not only did not reduce
